Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs

Juliana Quero Reimão, André Gustavo Tempone*

Departamento de Parasitologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo 351, 01246-000 São Paulo, SP, Brasil

The need for drug combinations to treat visceral leishmaniasis (VL) arose because of resistance to antimonials, the toxicity of current treatments and the length of the course of therapy. Calcium channel blockers (CCBs) have shown anti-leishmanial activity; therefore their use in combination with standard drugs could provide new alternatives for the treatment of VL. In this work, in vitro isobolograms of Leishmania (Leishmania) chagasi using promastigotes or intracellular amastigotes were utilised to identify the interactions between five CCBs and the standard drugs pentamidine, amphotericin B and glucantime. The drug interactions were assessed with a fixed ratio isobologram method and the fractional inhibitory concentrations (FICs), sum of FICs (ΣFICs) and the overall mean ΣFIC were calculated for each combination. Graphical isobologram analysis showed that the combination of nimodipine and glucantime was the most promising in amastigotes with an overall mean ΣFIC value of 0.79. Interactions between CCBs and the anti-leishmanial drugs were classified as indifferent according to the overall mean ΣFIC and the isobologram graphic analysis.

Key words: leishmaniasis - Leishmania therapy - calcium channel blockers - drug combinations - isobologram

Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by the Leishmania (Leishmania) donovani complex (Chappuis et al. 2007). The zoonotic form, in which dogs are the main reservoir in urban areas, is widely distributed in the Mediterranean basin, China, the Middle East and South America and is caused by Leishmania (Leishmania) infantum/Leishmania (Leishmania) chagasi (Herwaldt 1999, Chappuis et al. 2007). Although the disease is endemic in more than 60 countries with 200 million people at risk, 90% of the 500,000 cases are found in five countries: India, Bangladesh, Nepal, Sudan and Brazil (van Griensven et al. 2010).

In the past 70 years, the therapeutic arsenal for the treatment of VL has been extremely limited, consisting of the pentavalent antimonials (sodium stibogluconate and meglumine antimoniate), amphotericin B (and its lipid formulations) and miltefosine (Alvar et al. 2006). These drugs have crucial disadvantages, such as the length of treatment required, painful injection, toxicity, the emergence of resistance, dose-limiting nephrotoxicity, heat instability, high cost and poor patient compliance (van Griensven et al. 2010).

Calcium channel blockers (CCBs) are drugs used to treat heart diseases. This class of drugs inhibits the action of the calcium channels in cell membranes and potential indications are not limited to cardiovascular diseases. The class consists of three chemically distinct structural families: phenylalkylamines (e.g., verapamil), dihydropyridines (e.g., amlodipine, nimodipine) and benzothiazepines (e.g., diltiazem) (Motro et al. 2001). Considering that drug repurposing, also referred to as drug repositioning, is a promising approach to discover novel drug candidates to treat neglected diseases, the anti-parasitic activity of CCBs has been studied. It was demonstrated that nifedipine blocks the binding of Leishmania amastigotes to macrophages previously treated with the drug, suggesting that calcium has a role during the infection of macrophages by new parasites (Misra et al. 1991). There are also reports of the in vitro and in vivo activity of amlodipine and lacidipine against L. (L.) donovani (Palit & Ali 2008).

Based on their cardiac and peripheral activity, CCBs have been divided into the following classes (Singh 1986): (i) type I agents, exemplified by verapamil and related drugs (e.g., tiapamil, galopamil) and diltiazem (antiarrhythmics), (ii) type II agents, including nifedipine and other dihydropyridines, which are potent peripheral vasodilators with selective action on sympathetic reflexes, (iii) type III agents, including flunarizine and cinarizine (piperazine derivatives), which are potent dilators of peripheral vessels, and (iv) type IV agents show broad pharmacological action (e.g., perhexiline, lidoflazine and bepridil), which includes blocking the calcium flow in the heart and peripheral vessels and other electrophysiological actions.

The goals of the drug combinations are to prevent or delay the onset of resistance and relapses and also to increase the efficiency or reduce the course of treatment. These combinations have been the standard therapy of various viral, bacterial and parasitic diseases (White 1999, Olliaro & Taylor 2003). The need to investigate drug combinations for the therapy of leishmaniasis has been noted by several authors (Bryceson 2001, Sundar 2001, van Griensven et al. 2010). Drug combinations

Financial support: FAPES (08/09260-7), CNPq (to AGT) and FAPESP (08/1434-3 to JQR)
+ Corresponding author: atempone@ial.sp.gov.br
Received 4 July 2011
Accepted 25 October 2011
have been highlighted for VL in response to the need to overcome antimonial resistance, prolong the therapeutic lifespan of the drugs, shorten the length of treatment, improve patient compliance and increase cost-effectiveness (Olliari 2010).

Based on previous reports that demonstrate the anti-leishmanial activity of several CCBs (Tempone et al. 2009, Reimão et al. 2010), their in vitro activity when used in combination with standard drugs was explored with the goal of finding new alternatives for the treatment of leishmaniasis.

MATERIALS AND METHODS

Material - Sodium dodecyl sulphate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Thiazol blue), M-199 and Roswell Park Memorial Institute (RPMI)-PR1640 medium (without phenol red) were purchased from Sigma (St. Louis, MO, USA). Pentavalent antimony (glucantime, Aventis-Pharma-Brazil) and pentamidine (Sideron, Brazil) were used as standard drugs. Other analytical reagents were purchased from Sigma unless stated otherwise.

Animals - Golden hamsters (Mesocricetus auratus) and BALB/c mice were obtained from the Adolfo Lutz Institute of São Paulo and kept in sterile boxes with absorbent material while receiving food and water ad libitum. Golden hamsters were infected each month with amastigotes from the spleen to maintain the strain. BALB/c mice were used for obtaining peritoneal macrophages.

Parasites and macrophages - L. (L.) chagasi (MHOM/BR/1972/LD) promastigotes were grown in M-199 medium supplemented with 10% foetal calf serum (FCS) and 0.25% haemin at 24°C without addition of antibiotics. L. (L.) chagasi amastigotes were obtained by differential centrifugation from spleens of previously infected golden hamsters. The number of parasites was determined (Staub 1958) 60-70 days after infection. Macrophages were collected from the peritoneal cavity of BALB/c mice by washing with RPMI-1640 medium supplemented with 10% FCS and were maintained in a 5% CO₂-humidified incubator at 37°C (Tempone et al. 2008).

Determination of drug interactions - The interactions between drugs were evaluated in vitro by a modified isobologram method (Fivelman et al. 2004). The predetermined 50% inhibitory concentration (IC₅₀) values were used to determine the maximum concentrations of individual drugs, assuring that the IC₅₀ was in the fourth point of the serial dilution. Drugs were dissolved in dimethyl sulphoxide (DMSO) and diluted with medium. The highest concentrations of the solutions were prepared in proportions of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 of CCB and standard drug, respectively, which were serially diluted (base 2) to the seventh well of the microplate in duplicate.

Promastigotes assay - Promastigotes were counted in a Neubauer haemocytometer and seeded at 1 x 10⁶ well with a final volume of 200 µL. The initial concentrations used were 12 µg/mL for amiodipine, 12 µg/mL for bepridil, 100 µg/mL for lercanidipine, 100 µg/mL for nicardipine, 280 µg/mL for nimodipine, 1.5 µg/mL for pentamidine and 0.4 µg/mL for amphotericin B. Controls with DMSO and without drugs were performed.

Evaluation of fractional inhibitory concentrations (FICs) index, logobolagram construction and classification of the nature of interaction - FICs and the sum of FICs (ΣFICs) were calculated as follows: FIC of drug A = IC₅₀ of drug A in combination/IC₅₀ of drug A alone. The same equation was applied to the partner drug (drug B). ΣFICs = FIC drug A + FIC drug B. An overall mean ΣFIC was calculated for each combination and used to classify the nature of interaction as follows: synergy defined the mean ΣFIC < 0.5, indifference the mean ΣFIC between > 0.5 and ≤ 4 and antagonism the mean ΣFIC > 4 (Odds 2003). Isobolograms were constructed plotting the standard error of the mean (SEM) for each component of the dosage combination (Gessner 1995).

Statistical analysis - The data obtained represented the mean and standard deviation of duplicate samples from two independent assays. The IC₅₀ values were calculated using sigmoid dose-response curves with Graph Pad Prism 5.0 software and the 95% confidence intervals were included.

Ethics - All procedures performed on animals were approved by the Ethical Committee on Research of the Adolfo Lutz Institute/Pasteur Institute and were in agreement with the Guidelines for the Care and Use of Laboratory Animals from the National Academy of Sciences.

RESULTS

Evaluation of the anti-leishmanial activity of single drugs - L. (L.) chagasi was susceptible to all tested CCBs with IC₅₀ values that ranged from 0.8-30 µg/mL. As dem-
onstrated by the mitochondrial oxidative metabolism of parasites (MTT method), the tested drugs showed a leishmanicidal effect by killing 100% of parasites at the highest tested concentrations. These IC\textsubscript{50} values were obtained for the single drugs against promastigotes and are shown in Table I. Amlodipine was the most active CCB against both promastigotes and amastigotes.

**Combination studies** - The combination of amlo-
dipine, bepridil, lercanidipine, nicardipine and nimo-
dipine with the anti-leishmanial drugs amphotericin B and pentamidine in *L. (L.) chagasi* promastigotes indicated an indifferent interaction. This was demonstrated by analysis of the overall mean ΣFICs, which ranged from 1.13-1.7 (Table II). According to the graphic analysis of the isobolograms using promastigotes (Fig. 1), indifference was observed within all combinations because all points (P\textsubscript{2}, P\textsubscript{4}) corresponding to the proportions of 4:1, 3:2, 2:3 and 1:4 of CCB and standard anti-leishmanial drug, respectively) are located above the additivity line. The combination of amlodipine and nimodipine with glaucan-
time and amphotericin B in *L. (L.) chagasi* intracellular amastigotes was classified as indifferent according the overall mean ΣFICs, which ranged from 0.79-1.43 (Table II). The graphic analysis of the isobologram (Fig. 2) showed that, in spite of some points being located below the additivity line (point P\textsubscript{4} of amlodipine:amphotericin B; point P\textsubscript{5} of amlodipine:glaucantime and points P\textsubscript{6} and P\textsubscript{7} of nimodipine:glaucantime), the SEM should also be considered in the analysis. The combination of nimodipine and glucantime (Fig. 2D) showed synergy in three of the points in the isobolgram, with the most syner
gic effect seen in the point P\textsubscript{5} (ratio 2:3 of nimodipine:glaucantime). However, according to the adopted classification, this drug combination was not considered syner
gic because the overall mean ΣFIC of this combination was 0.79 (Table II).

**DISCUSSION**

Infectious diseases such as tuberculosis, leprosy, ma-
laria and acquired immune deficiency syndrome were only considered to be under therapeutic control after the introduction of drug combinations. Combinatorial treat-
ments can only boost the action of the different ther-
apeutic compounds, but they may also help to avoid the development of parasite resistance (Coura 2009). This is the first report that investigates the in vitro activity of combinations of calcium antagonists and standard drugs for leishmaniasis. Despite the previously observed anti-
leishmanial activity of the CCBs used in the study (Re-
imão et al. 2010), the overall mean ΣFIC and the isobo-
lograms obtained show no physicochemical or biological interactions between the CCBs and the standard drugs.

The isobologram is a graphical representation of the effective dose, or FIC value, of two drugs when adminis-
tered together. In this graph, the intercepts are the points that define the line of additivity (junction of points P\textsubscript{2} and P\textsubscript{4}) (Figs 1, 2) and all points in this line are the co-
ordinates that theoretically represent the doses of drug pairs (P\textsubscript{2}-P\textsubscript{4}) (Figs 1, 2). This graphical representation provides an overview of the isobologram of theoretical additive doses, but ΣFIC values are preferred for statistical analysis (Tallarida et al. 1997).
Fig. 1: representative isobolograms of in vitro interactions of calcium channel blockers (CCBs) and the partner drug against *Leishmania (Leishmania) chagasi* promastigotes. The half maximal inhibitory concentration (IC_{50}) of amlodipine, bepridil, lercanidipine, nicardipine and nimodipine was plotted in the abscissa and the IC_{50} of amphotericin B and pentamidine was plotted in the ordinate. The plotted points are IC_{50}s of each fixed ratio combination serially diluted. Bars around points correspond to calculated standard errors of the mean. Points P_{1}-P_{6} correspond to the proportion of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 of CCB and standard anti-leishmanial drug, respectively. The bold line corresponds to the predicted positions of the experimental points for a simple additive effect. The dotted line corresponds to the additivity line range of confidence.
in this report. The isobologram graph made from FIC values has been widely used to represent the interaction between two drugs (Fivelman et al. 2004). However, it is also possible to use the IC$_{50}$ values and their respective confidence intervals (Gessner 1995). Thus, the graph with standard error bars can be more informative and was used in the present work.

The FIC values demonstrate that paired combinations of agents can exert inhibitory effects higher than the sum of their effects alone (synergy; FIC < 1.0) or smaller than the sum of their effects alone (antagonism; FIC > 1.0) (Berembaum 1978). However, Odds (2003) proposed the interpretation of FIC data as “synergy” when FIC ≤ 0.5, “antagonism” when FIC ≥ 4.0 and “no interaction” when FIC > 0.5 < 4.0.

Most relevant information for drug combinations is obtained with the intracellular amastigote assay. However, the use of axenic promastigotes can also provide useful data. It is important to consider that the presence of the host cell (macrophages) could interfere within the synergism/antagonism of the drug combinations during studies against Leishmania. Thus, susceptibility studies using the two parasite stages (promastigotes and intracellular amastigotes) can provide additional information about the distinct action of the drug combinations in addition to that obtained from ordinary macrophage activation.

Calcium antagonists have shown anti-parasitic properties (Misra et al. 1991, Núñez-Vergara et al. 1998, Tempone et al. 2009, Reimão et al. 2010, 2011). Other studies have reported that amlodipine reverses the in vitro chloroquine resistance in Plasmodium falciparum (Basco & Le Bras 1991) and can also increase chloroquine accumulation inside the infected erythrocytes. Therefore, combination therapy of amlodipine and chloroquine might be a useful therapeutic strategy against chloroquine-resistant malaria (Deloron et al. 1991). In addition, the 1,4-dihydropyridine nicardipine showed in vitro activity against P. falciparum (IC$_{50}$ = 4.3 μM) (Tanabe et al. 1989).

Bepridil, an anti-anginal pyrrolidine drug, demonstrated effectiveness in vitro against a panel of visceral and cutaneous species of Leishmania, with IC$_{50}$ values ranging from 3-7 μM (Tempone et al. 2009, Reimão et al. 2011). It has also demonstrated activity against other protozoans, such as Toxoplasma gondii (Song et al. 2004), P. falciparum (IC$_{50}$ = 2.63 μM) (Mahmoudi et al. 2006), Trypanosoma cruzi (Reimão et al. 2011) and Entamoeba species (Makioka et al. 2001). However, it lacks activity in an experimental L. (L.) chagasi model (Reimão et al. 2011).

In a previous report, eight clinically used 1,4-dihydropyridines demonstrated in vitro anti-leishmanial activity with IC$_{50}$ values ranging from 5.35-176.24 μM (Reimão et al. 2010). Amlodipine, lercanidipine, nicardipine and nimodipine were among the most active CCBs against L. (L.) chagasi amastigotes. Based on previous studies, CCBs were selected for drug combination assays, but none of the tested CCBs increased pentamidine, amphotericin B or glucantime in vitro activity.

Other promising pharmacological activities of CCBs have been reported in Leishmania sp., including the reversal of antimony resistance in clinical isolates of L. (L.) donovani (Valiathan et al. 2006). According to Misra et al. (1991), nifedipine and verapamil could effectively

---

**Fig. 2:** representative isobolograms of in vitro interactions of calcium channel blockers (CCBs) and the partner drug against Leishmania (Leishmania) chagasi intracellular amastigotes. The half maximal inhibitory concentration (IC$_{50}$) of amlodipine and nimodipine was plotted in the abscissa and the IC$_{50}$ of amphotericin B and glucantime was plotted in the ordinate. The plotted points are IC$_{50}$s of each fixed ratio combination serially diluted. Bars around points correspond to calculated standard errors of the mean. Points P1-P6 correspond to the proportion of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 of CCB and standard anti-leishmanial drug, respectively. The bold line corresponds to the predicted positions of the experimental points for a simple additive effect. The dotted line corresponds to the additivity line range of confidence.
inhibit the infection of macrophages by *L. (L.) donovani*, although no anti-parasitic effect could be observed. Palit and Ali (2008) also showed that lacidipine, amlodipine, verapamil and diltiazem inhibited Ca\(^{2+}\) uptake by *Leishmania*, but only lacidipine and amlodipine showed in vivo anti-leishmanial activity. Therefore, studying the action mechanisms of CCBs could prove useful for developing drug design studies and novel strategies for reversing the resistance of *Leishmania* spp.

In vitro combination assays are an advantageous and rational methodology for the screening of synergic drug combinations. However, they do not provide other important information, such as pharmacokinetic (Seifert et al. 2011) and pharmacodynamic interactions (Seifert & Croft 2006). This can only be measured by animal assays. Considering the in vitro anti-leishmanial activity of the studied CCBs, further in vivo studies may be considered to evaluate possible drug interactions in VL.

**ACKNOWLEDGEMENTS**

To Dr Karin Seifert (London School of Hygiene and Tropical Medicine), for suggestions during paper preparation.

**REFERENCES**


Valiathan R, Dubey ML, Mahajan RC, Malla N 2006. *Leishmania donovani*: effect of verapamil on *in vitro* susceptibility of pro-
mastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 114: 103-108.

